Blood Pressure Drug Recall
Inventia Healthcare Recalls Over 25,000 Blood Pressure Medication Bottles Nationwide
Anonymous
Key Points
1
The September recall covers bottles from batch RISA24002, with an expiration date of March 2027, according to one report.
2
The recalled tablets were packaged in bottles of 100 or 1,000; the broader recall report lists an April 2027 expiration date for the affected product.
3
The recalls were announced on June 5 and September 3, and the later recall was not widely publicized until the FDA posted an enforcement report, according to one article.
4
One report said no illnesses or injuries related to the recall had been reported at the time of publication.
5
A Class II recall is the FDA’s second-highest recall classification, according to one report.
Inventia Healthcare has recalled over 25,000 bottles of chlorthalidone, a common blood pressure medication, after the tablets failed dissolution tests. WOWO News reported that the recalled 25-milligram tablets may not dissolve properly in the body, potentially reducing how much medication patients absorb and limiting blood pressure control. The FDA classified both recalls as Class II, meaning possible temporary health effects, though no illnesses have been reported.
The September recall alone covers 13,567 bottles from batch RISA24002 with an expiration date of March 2027, while an earlier June recall involved 11,460 bottles. Wide Open Country noted that Inventia Healthcare Limited of India and its New Jersey subsidiary issued the recalls after quality testing revealed the dissolution problem. Patients with affected bottles should contact their pharmacist or doctor but must not stop taking chlorthalidone without medical guidance.
What Went Wrong With the Tablets
The recalled chlorthalidone tablets failed dissolution tests, which check whether pills break down correctly in the stomach and intestines. WOWO News explained that when tablets do not dissolve properly, the body cannot absorb the full dose of medication. For blood pressure drugs, this failure means patients may not receive enough medicine to control their hypertension effectively, creating a safety risk over time.
Why This Recall Is Not Considered Urgent
The FDA assigned both recalls a Class II rating, the agency's second-highest classification level. News SSB Crack reported this designation means possible temporary or medically reversible health consequences, while serious harm is unlikely. Class II recalls indicate the problem could affect treatment but is not immediately life-threatening, which is why patients can safely consult their doctor before stopping the medication.
How to Check If Your Bottle Is Affected
Patients should examine their chlorthalidone bottles for the batch number RISA24002 and expiration dates between March and April 2027. The recalled tablets came in bottles of 100 or 1,000 units. KEZJ advised anyone who may have an affected product to contact their pharmacy immediately to verify whether their specific bottle is part of the recall and receive guidance on next steps.
Why This Recall Stayed Quiet Until Now
The first recall was announced June 5, and the September recall followed on September 3, but Power Talk 1460 noted the second recall received little public attention until the FDA posted an enforcement report. The delayed publicity meant many patients and pharmacies may not have learned about the recall for weeks. Wide Open Country highlighted this communication gap, noting that affected customers may still be unaware and should check their medicine cabinets proactively.
Sentiment
Mostly NegativeNEGATIVENEUTRALPOSITIVE
Publishers
19
Articles
43
Reach
62
Topics
A
AnonymousAuthor
